SEARCH

SEARCH BY CITATION

References

  • Andressen K. W., Norum J. H., Levy F. O. and Krobert K. A. (2006) Activation of adenylyl cyclase by endogenous G(s)-coupled receptors in human embryonic kidney 293 cells is attenuated by 5-HT(7) receptor expression. Mol. Pharmacol. 69, 207215.
  • Arimura K., Ago T., Kamouchi M., Nakamura K., Ishitsuka K., Kuroda J., Sugimori H., Ooboshi H., Sasaki T. and Kitazono T. (2012) PDGF receptor beta signaling in pericytes following ischemic brain injury. Curr. Neurovasc. Res. 9, 19.
  • Bacon W. L. and Beck S. G. (2000) 5-Hydroxytryptamine(7) receptor activation decreases slow afterhyperpolarization amplitude in CA3 hippocampal pyramidal cells. J. Pharmacol. Exp. Ther. 294, 672679.
  • Beazely M. A., Tong A., Wei W. L., Van Tol H., Sidhu B. and MacDonald J. F. (2006) D2-class dopamine receptor inhibition of NMDA currents in prefrontal cortical neurons is platelet-derived growth factor receptor-dependent. J. Neurochem. 98, 16571663.
  • Beazely M. A., Lim A., Li H., Trepanier C., Chen X., Sidhu B. and Macdonald J. F. (2009) Platelet-derived growth factor selectively inhibits NR2B-containing N-methyl-D-aspartate receptors in CA1 hippocampal neurons. J. Biol. Chem. 284, 80548063.
  • Bonaventure P., Dugovic C., Kramer M. et al. (2012) Translational evaluation of JNJ-18038683, a 5-HT7 receptor antagonist, on REM sleep and in major depressive disorder. J. Pharmacol. Exp. Ther. 342, 429440.
  • Carrier R. L., Ma T. C., Obrietan K. and Hoyt K. R. (2006) A sensitive and selective assay of neuronal degeneration in cell culture. J. Neurosci. Methods 154, 239244.
  • Chapin E. M. and Andrade R. (2001a) A 5-HT(7) receptor-mediated depolarization in the anterodorsal thalamus. I. Pharmacological characterization. J. Pharmacol. Exp. Ther. 297, 395402.
  • Chapin E. M. and Andrade R. (2001b) A 5-HT(7) receptor-mediated depolarization in the anterodorsal thalamus. II. Involvement of the hyperpolarization-activated current I(h). J. Pharmacol. Exp. Ther. 297, 403409.
  • Crider J. Y., Williams G. W., Drace C. D., Katoli P., Senchyna M. and Sharif N. A. (2003) Pharmacological characterization of a serotonin receptor (5-HT7) stimulating cAMP production in human corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 44, 48374844.
  • Duncan M. J. and Congleton M. R. (2010) Neural mechanisms mediating circadian phase resetting by activation of 5-HT(7) receptors in the dorsal raphe: roles of GABAergic and glutamatergic neurotransmission. Brain Res. 1366, 110119.
  • Egawa-Tsuzuki T., Ohno M., Tanaka N., Takeuchi Y., Uramoto H., Faigle R., Funa K., Ishii Y. and Sasahara M. (2004) The PDGF B-chain is involved in the ontogenic susceptibility of the developing rat brain to NMDA toxicity. Exp. Neurol. 186, 8998.
  • Ellis J. A., Canoll P., McCormick P. C., 2nd, Feldstein N. A., Anderson R. C., Angevine P. D., Kaiser M. G., McCormick P. C., Bruce J. N. and Ogden A. T. (2012a) Platelet-derived growth factor receptor (PDGFR) expression in primary spinal cord gliomas. J. Neurooncol. 106, 235242.
  • Ellis J. A., Castelli M., Bruce J. N., Canoll P. and Ogden A. T. (2012b) Retroviral delivery of PDGF to spinal cord progenitor cells drives the formation of intramedullary gliomas. Neurosurgery 70, 198204.
  • Figiel M., Maucher T., Rozyczka J., Bayatti N. and Engele J. (2003) Regulation of glial glutamate transporter expression by growth factors. Exp. Neurol. 183, 124135.
  • Galici R., Boggs J. D., Miller K. L., Bonaventure P. and Atack J. R. (2008) Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behav. Pharmacol. 19, 153159.
  • Gill C. H., Soffin E. M., Hagan J. J. and Davies C. H. (2002) 5-HT7 receptors modulate synchronized network activity in rat hippocampus. Neuropharmacology 42, 8292.
  • Harsing L. G., Jr, Prauda I., Barkoczy J., Matyus P. and Juranyi Z. (2004) A 5-HT7 heteroreceptor-mediated inhibition of [3H]serotonin release in raphe nuclei slices of the rat: evidence for a serotonergic-glutamatergic interaction. Neurochem. Res. 29, 14871497.
  • Hirst W. D., Price G. W., Rattray M. and Wilkin G. P. (1997) Identification of 5-hydroxytryptamine receptors positively coupled to adenylyl cyclase in rat cultured astrocytes. Br. J. Pharmacol. 120, 509515.
  • van Hooft J. A. and Vijverberg H. P. (2000) 5-HT(3) receptors and neurotransmitter release in the CNS: a nerve ending story? Trends Neurosci. 23, 605610.
  • Hoyer S. (2002) The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J. Neural. Transm. 109, 9911002.
  • Hoyer D. and Martin G. (1997) 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 36, 419428.
  • Iihara K., Sasahara M., Hashimoto N., Uemura Y., Kikuchi H. and Hazama F. (1994) Ischemia induces the expression of the platelet-derived growth factor-B chain in neurons and brain macrophages in vivo. J. Cereb. Blood Flow Metab. 14, 818824.
  • Iihara K., Sasahara M., Hashimoto N. and Hazama F. (1996) Induction of platelet-derived growth factor beta-receptor in focal ischemia of rat brain. J. Cereb. Blood Flow Metab. 16, 941949.
  • Kobe F., Guseva D., Jensen T. P. et al. (2012) 5-HT7R/G12 signaling regulates neuronal morphology and function in an age-dependent manner. J. Neurosci. 32, 29152930.
  • Kovalenko M., Gazit A., Bohmer A., Rorsman C., Ronnstrand L., Heldin C. H., Waltenberger J., Bohmer F. D. and Levitzki A. (1994) Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 54, 61066114.
  • Krobert K. A., Bach T., Syversveen T., Kvingedal A. M. and Levy F. O. (2001) The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution. Naunyn Schmiedebergs Arch. Pharmacol. 363, 620632.
  • Krobert K. A., Andressen K. W. and Levy F. O. (2006) Heterologous desensitization is evoked by both agonist and antagonist stimulation of the human 5-HT(7) serotonin receptor. Eur. J. Pharmacol. 532, 110.
  • Kroeze W. K., Kristiansen K. and Roth B. L. (2002) Molecular biology of serotonin receptors structure and function at the molecular level. Curr. Top. Med. Chem. 2, 507528.
  • Krupinski J., Issa R., Bujny T., Slevin M., Kumar P., Kumar S. and Kaluza J. (1997) A putative role for platelet-derived growth factor in angiogenesis and neuroprotection after ischemic stroke in humans. Stroke 28, 564573.
  • Kvachnina E., Liu G., Dityatev A., Renner U., Dumuis A., Richter D. W., Dityateva G., Schachner M., Voyno-Yasenetskaya T. A. and Ponimaskin E. G. (2005) 5-HT7 receptor is coupled to G alpha subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology. J. Neurosci. 25, 78217830.
  • Lai T. W., Shyu W. C. and Wang Y. T. (2011) Stroke intervention pathways: NMDA receptors and beyond. Trends Mol. Med. 17, 266275.
  • Leopoldo M., Lacivita E., De Giorgio P., Fracasso C., Guzzetti S., Caccia S., Contino M., Colabufo N. A., Berardi F. and Perrone R. (2008) Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III. J. Med. Chem. 51, 58135822.
  • Mahe C., Bernhard M., Bobirnac I., Keser C., Loetscher E., Feuerbach D., Dev K. K. and Schoeffter P. (2004) Functional expression of the serotonin 5-HT7 receptor in human glioblastoma cell lines. Br. J. Pharmacol. 143, 404410.
  • Marcos B., Cabero M., Solas M., Aisa B. and Ramirez M. J. (2010) Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects. Int. J. Neuropsychopharmacol. 13, 775784.
  • Mork A., Pehrson A., Brennum L. T. et al. (2012) Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J. Pharmacol. Exp. Ther. 340, 666675.
  • Peng F., Dhillon N., Callen S., Yao H., Bokhari S., Zhu X., Baydoun H. H. and Buch S. (2008) Platelet-derived growth factor protects neurons against gp120-mediated toxicity. J. Neurovirol. 14, 6272.
  • Quintero J. E. and McMahon D. G. (1999) Serotonin modulates glutamate responses in isolated suprachiasmatic nucleus neurons. J. Neurophysiol. 82, 533539.
  • Roberts C., Thomas D. R., Bate S. T. and Kew J. N. (2004) GABAergic modulation of 5-HT7 receptor-mediated effects on 5-HT efflux in the guinea-pig dorsal raphe nucleus. Neuropharmacology 46, 935941.
  • Romero G., Pujol M. and Pauwels P. J. (2006) Reanalysis of constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists. Naunyn Schmiedebergs Arch. Pharmacol. 374, 3139.
  • Roussidis A. E., Theocharis A. D., Tzanakakis G. N. and Karamanos N. K. (2007) The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer. Curr. Med. Chem. 14, 735743.
  • Sakata M., Yanamoto H., Hashimoto N., Iihara K., Tsukahara T., Taniguchi T. and Kikuchi H. (1998) Induction of infarct tolerance by platelet-derived growth factor against reversible focal ischemia. Brain Res. 784, 250255.
  • Shiba M., Suzuki H., Fujimoto M., Shimojo N., Imanaka-Yoshida K., Yoshida T., Kanamaru K., Matsushima S. and Taki W. (2013) Role of platelet-derived growth factor in cerebral vasospasm after subarachnoid hemorrhage in rats. Acta Neurochir. Suppl. 115, 219223.
  • Shih A. H. and Holland E. C. (2006) Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett. 232, 139147.
  • Smith B. N., Sollars P. J., Dudek F. E. and Pickard G. E. (2001) Serotonergic modulation of retinal input to the mouse suprachiasmatic nucleus mediated by 5-HT1B and 5-HT7 receptors. J. Biol. Rhythms 16, 2538.
  • Smits A., Kato M., Westermark B., Nister M., Heldin C. H. and Funa K. (1991) Neurotrophic activity of platelet-derived growth factor (PDGF): Rat neuronal cells possess functional PDGF beta-type receptors and respond to PDGF. Proc. Natl Acad. Sci. USA 88, 81598163.
  • Soriano F. X. and Hardingham G. E. (2007) Compartmentalized NMDA receptor signalling to survival and death. J. Physiol. 584, 381387.
  • Stam N. J., Roesink C., Dijcks F., Garritsen A., van Herpen A. and Olijve W. (1997) Human serotonin 5-HT7 receptor: cloning and pharmacological characterisation of two receptor variants. FEBS Lett. 413, 489494.
  • Thomas D. R. and Hagan J. J. (2004) 5-HT7 receptors. Curr. Drug Targets CNS Neurol. Disord. 3, 8190.
  • Thomas D. R., Middlemiss D. N., Taylor S. G., Nelson P. and Brown A. M. (1999) 5-CT stimulation of adenylyl cyclase activity in guinea-pig hippocampus: evidence for involvement of 5-HT7 and 5-HT1A receptors. Br. J. Pharmacol. 128, 158164.
  • Tokarski K., Zahorodna A., Bobula B., Grzegorzewska M., Pitra P. and Hess G. (2005) Repeated administration of citalopram and imipramine alters the responsiveness of rat hippocampal circuitry to the activation of 5-HT7 receptors. Eur. J. Pharmacol. 524, 6066.
  • Toohey N., Klein M. T., Knight J., Smith C. and Teitler M. (2009) Human 5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other “inactivating antagonists”. Mol. Pharmacol. 76, 552559.
  • Tseng H. C. and Dichter M. A. (2005) Platelet-derived growth factor-BB pretreatment attenuates excitotoxic death in cultured hippocampal neurons. Neurobiol. Dis. 19, 7783.
  • Uzun S., Kozumplik O., Mimica N. and Folnegovic-Smalc V. (2005) Aripiprazole: an overview of a novel antipsychotic. Psychiatr. Danub. 17, 6775.
  • Valenzuela C. F., Xiong Z., MacDonald J. F., Weiner J. L., Frazier C. J., Dunwiddie T. V., Kazlauskas A., Whiting P. J. and Harris R. A. (1996) Platelet-derived growth factor induces a long-term inhibition of N-methyl-D-aspartate receptor function. J. Biol. Chem. 271, 1615116159.
  • Vasefi M. S., Kruk J. S., Liu H., Heikkila J. J. and Beazely M. A. (2012) Activation of 5-HT7 receptors increases neuronal platelet-derived growth factor beta receptor expression. Neurosci. Lett. 511, 6569.
  • Weigel M. T., Meinhold-Heerlein I., Bauerschlag D. O., Schem C., Bauer M., Jonat W., Maass N. and Mundhenke C. (2009) Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling. Cancer Lett. 273, 7079.
  • Wu X., Zhu D., Jiang X., Okagaki P., Mearow K., Zhu G., McCall S., Banaudha K., Lipsky R. H. and Marini A. M. (2004) AMPA protects cultured neurons against glutamate excitotoxicity through a phosphatidylinositol 3-kinase-dependent activation in extracellular signal-regulated kinase to upregulate BDNF gene expression. J. Neurochem. 90, 807818.
  • Yao H., Peng F., Dhillon N., Callen S., Bokhari S., Stehno-Bittel L., Ahmad S. O., Wang J. Q. and Buch S. (2009a) Involvement of TRPC channels in CCL2-mediated neuroprotection against tat toxicity. J. Neurosci. 29, 16571669.
  • Yao H., Peng F., Fan Y., Zhu X., Hu G. and Buch S. J. (2009b) TRPC channel-mediated neuroprotection by PDGF involves Pyk2/ERK/CREB pathway. Cell Death Differ. 16, 16811693.